Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jun;30(6):1422-5.
doi: 10.1038/leu.2015.320. Epub 2015 Nov 20.

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone

G E Nybakken  1 , J Canaani  2 , D Roy  3 , J D Morrissette  4 , C D Watt  4 , N P Shah  5 , C C Smith  5 , A Bagg  4 , M Carroll  2   6 , A E Perl  2
Affiliations
Clinical Trial

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone

G E Nybakken et al. Leukemia. 2016 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

AEP has served as a consultant to Ambit Biosciences, Astellas Pharmaceuticals and Arog Pharmaceuticals. CCS received clinical trial grant funding from Astellas. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Quizartinib therapy reduces marrow blast burden by the induction of either differentiation or cytotoxicity responses. (a, b) Comparison of blast burden and marrow cellularity at baseline and at best response time points. (c, d) Representative photomicrographs of two patients with differentiation and cytotoxic responses. (e) Graph of FLT3-ITD:WT allelic ratio, organized by color according to response. The ratio has been converted to ITD frequency (ITD/ITD+WT) for ease of graphical display.
See this image and copyright information in PMC

References

    1. Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >= 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. 2012;120:48.
    1. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649. - PubMed
    1. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260–263. - PMC - PubMed
    1. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885–3891. - PubMed
    1. Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122:239–242. - PubMed

Publication types

MeSH terms

LinkOut - more resources